Phase II study of the activity and tolerability of a combined regimen of high-dose epirubicin and cisplatin in stage IIIb and IV non-small cell lung cancer

M. Clerici, F. De Marinis, E. Piazza, L. Frontini, E. Tucci, S. Barni, S. Bretti, G. Luporini, C. Intini

Research output: Contribution to journalArticle

Abstract

Aim: To explore the feasibility and activity of a combined regimen of high-dose epirubicin and cisplatin as an alternative to current treatments for non-small cell lung cancer (NSCLC). Method: Forty-four patients with stage IIIb or IV NSCLC, median Karnofsky index 90, were enrolled. Epirubicin (60 mg/m2) was administered on days 1 and 2 and cisplatin (100 mg/m2) on day 1. Treatment was repeated every 21 days for a maximum of six cycles. A hematopoietic growth factor (G-CSF) was used only for patients reaching codified nadir count values. Results: A total of 130 cycles were administered with a mean of 2.9 cycles per patient. Of 41 assessable patients one showed a complete response and 15 had partial responses (overall response rate, 39%). Grade 3 or 4 leukopenia and grade 3 hemoglobin toxicity were seen in 40% and 14%, respectively, of the administered cycles. The most common nonhematologic toxic events were nausea and vomiting, mucositis, anorexia, and asthenia. Conclusions: This epirubicin-cisplatin regimen seemed effective and was generally well tolerated, and therefore suitable for use in an outpatient setting.

Original languageEnglish
Pages (from-to)669-672
Number of pages4
JournalTumori
Volume84
Issue number6
Publication statusPublished - 1998

Keywords

  • Chemotherapy
  • Cisplatin
  • Epirubicin
  • High-dose chemotherapy
  • NSCLC

ASJC Scopus subject areas

  • Cancer Research

Fingerprint Dive into the research topics of 'Phase II study of the activity and tolerability of a combined regimen of high-dose epirubicin and cisplatin in stage IIIb and IV non-small cell lung cancer'. Together they form a unique fingerprint.

  • Cite this

    Clerici, M., De Marinis, F., Piazza, E., Frontini, L., Tucci, E., Barni, S., Bretti, S., Luporini, G., & Intini, C. (1998). Phase II study of the activity and tolerability of a combined regimen of high-dose epirubicin and cisplatin in stage IIIb and IV non-small cell lung cancer. Tumori, 84(6), 669-672.